Alaunos Therapeutics, Inc. TCRT
Alaunos Therapeutics, Inc. (Nasdaq: TCRT) is a cardio-renal-metabolic drug developer. Its lead program, ALN1003, is in Pre-clinical for obesity and metabolic disorders (MASLD, insulin resistance). Its next catalyst on record is VLR199: Alaunos, after acquiring Velaris and a $350M private placement, expects clinical proof-of-concept data for VLR199 (ActRIIA-Fc ligand trap, PAH) in 2028. (2028).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: VLR199 — Alaunos, after acquiring Velaris and a $350M private placement, expects clinical proof-of-concept data for VLR199 (ActRIIA-Fc ligand trap, PAH) in 2028. (2028). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| TCR-T Library (legacy, discontinued Aug 2023) | solid tumors | cell therapy | Phase 1 |
| ALN1003 | obesity / MASLD | small molecule | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other pre-clinical cardio-renal-metabolic companies
- Editas Medicine, Inc. EDIT
- Atrium Therapeutics, Inc. RNA
- Cellectis S.A. CLLS
- NewcelX Ltd. NCEL
- Fractyl Health, Inc. GUTS
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.